Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study

Annals of Oncology

Volumn 26, Issue 4, 2015, Pages 798-803

  Di Giacomo, A M ^a   Ascierto, P A ^b   Queirolo, P ^c   Pilla, L ^d   Ridolfi, R ^e   Santinami, M ^f   Testori, A ^g   Simeone, E ^b   Guidoboni, M ^e   Maurichi, A ^f   Orgiano, L ^c   Spadola, G ^g   Del Vecchio, M ^f   Danielli, R ^a   Calabro L ^a   Annesi, D ^a   Giannarelli, D ^h   Maccalli, C ^a,i   Fonsatti, E ^a   Parmiani, G ^d   Maio, Michele ^a   more..

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

ⁱ Italian Network for Tumor Biotherapy (NIBIT)   (Italy)

Author keywords

CTLA 4; Fotemustine; Immunotherapy; Ipilimumab; Metastatic melanoma

Indexed keywords

B RAF KINASE; CD3 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; FOTEMUSTINE; INDUCIBLE T CELL COSTIMULATOR; IPILIMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG ERUPTION; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MEMORY CELL; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; STEREOTACTIC RADIOSURGERY; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOLOGICAL THERAPY; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SKIN NEOPLASMS; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL THERAPY; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84926507093     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu577     Document Type: Article

References (24)

1. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19: 5300-5309.
2. Kee D, McArthur G. Targeted therapies for cutaneous melanoma. Hematol Oncol Clin North Am 2014; 28: 491-505.
3. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
4. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
5. Maio M, Bondarenko I, Robert C et al. Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma. Eur J Cancer 2013; 49(2 suppl): 3704.
6. Di Giacomo AM, Calabrò L, Danielli R et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013; 62: 1021-1028.
7. Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur J Cancer 2013; 49(3 suppl): LB24.
8. Davies MA, Liu P, McIntyre S et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011; 117: 1687-1696.
9. Staudt M, Lasithiotakis K, Leiter U et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010; 102: 1213-1218.
10. Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-465.
11. Maio M, Di Giacomo AM, Robert C, Eggermont A. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol 2013; 25: 166-172.
12. Maio M, Ascierto P, Testori A et al. The cost of unresectable stage III or stage IV melanoma in Italy. J Exp Clin Cancer Res 2012; 31: 91.
13. Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118-1125.
14. Di Giacomo AM, Ascierto PA, Pilla L et al. A phase 2, open-label, single-arm study to investigate the combination of ipilimumab and fotemustine in patients with advanced melanoma: the NIBIT-M1 trial. Lancet Oncol 2012; 13: 879-886.
15. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
16. Brookmeyer R, Crowley JA. Confidence interval for the median survival time. Biometrics 1982; 38: 29-41.
17. Sznol M, Kluger HM, Callahan MK et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol 2014; 32(5 suppl): LBA9003.
18. Weber JS, Hamid O, Chasalow SD et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother 2012; 35: 89-97.
19. Wang W, Yu D, Sarnaik AA et al. Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med 2012; 10: 146.
20. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 2011; 71: 5445-5454.
21. Guedan S, Chen X, Madar A et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 2014; 124: 1070-80.
22. Shahabi V, Whitney G, Hamid O et al. Assessment of association between BRAFV600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother 2012; 61: 733-737.
23. Ascierto PA, Simeone E, Chiarion-Sileni V et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of ipilimumab expanded access programme (EAP). Cancer Invest 2014; 32: 144-149.
24. Neyns B, Weber J, Lebbè C et al. Ipilimumab retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials. J Clin Oncol 2013; (31 suppl): 9059.